Financial Performance - The company reported net losses of $17.7 million for Q3 2024, compared to $10.1 million for Q3 2023, and $45.6 million for the nine months ended September 30, 2024, compared to $35.0 million for the same period in 2023[63]. - Net loss for Q3 2024 was $17.7 million, a 76% increase from a net loss of $10.1 million in Q3 2023[75]. - Net cash used in operating activities was $42.3 million for the nine months ended September 30, 2024, compared to $29.0 million in 2023[85]. - The company does not expect to generate revenue from product sales in the foreseeable future and will need substantial additional funding to support ongoing operations[68]. Cash and Funding - As of September 30, 2024, the company had an accumulated deficit of $136.2 million and cash and cash equivalents of $159.1 million, which is expected to fund operations for at least the next twelve months[61]. - The company has raised an aggregate of $288.6 million since inception through various financing methods, including the sale of convertible preferred stock and common stock[61]. - Net cash provided by financing activities was $172.8 million for the nine months ended September 30, 2024, primarily from the sale of shares and proceeds from the Merger[89]. - The company anticipates needing additional capital to fund ongoing operations and research and development activities[84]. Expenses - Research and development expenses increased by 76% to $14.3 million in Q3 2024 from $8.1 million in Q3 2023[75]. - General and administrative expenses rose by 169% to $5.3 million in Q3 2024 compared to $2.0 million in Q3 2023[78]. - Total operating expenses for Q3 2024 were $19.6 million, a 94% increase from $10.1 million in Q3 2023[75]. - General and administrative expenses for the nine months ended September 30, 2024, were $11.8 million, a 115% increase from $5.5 million in the same period of 2023[79]. Clinical Trials and Development - The Phase 1a trial for the lead asset TX45 showed favorable results, with no severe adverse events and a favorable pharmacokinetic/pharmacodynamic relationship[61]. - The Phase 1b hemodynamic clinical trial for TX45 is enrolling ahead of plan, with topline results expected in late Q1 or early Q2 2025[61]. - The APEX Phase 2 clinical trial for TX45 commenced in October 2024, with topline results anticipated in 2026[61]. - The company plans to initiate a Phase 1 clinical trial for TX2100 in Q4 2025 or Q1 2026, pending IND enabling studies[61]. Merger and Financing - The merger with AVROBIO was completed on June 20, 2024, resulting in Legacy Tectonic securityholders owning approximately 38.5% of the outstanding shares on a diluted basis[65]. - Concurrently with the merger, the company raised $96.6 million through a Subscription Agreement at a price of $12.40 per share[66]. - The company issued SAFEs for proceeds of $34.1 million in October and December 2023, recorded as liabilities at fair value[73]. Obligations and Commitments - As of September 30, 2024, the company's total contractual obligations and commitments amount to $3.788 million, with $2.163 million due within one year[92]. - The company has a one-time license fee obligation of $170,000 to Harvard, payable in equal installments over three years, with the final installment made in July 2024[94]. - The company is obligated to pay up to $8.5 million in milestone payments for products granted FDA marketing authorization under the Harvard License Agreement[94]. - The company has a license agreement with Alloy Therapeutics, which includes total milestone payments of $4.8 million and annual commercial payments in the low seven digits for the first six years of sales[95]. Interest Income and Financial Sensitivity - Interest income surged by 1,912% to $1.9 million in Q3 2024 from $97,000 in Q3 2023, primarily due to increased cash and cash equivalents[75]. - Interest income increased by $2.0 million for the nine months ended September 30, 2024, primarily due to an increase in cash and cash equivalents resulting from the Merger[83]. - The company’s financial condition is sensitive to interest rate changes, but a 10% change in market interest rates would not materially affect the fair market value of its investment portfolio[102].

Financial Position - Cash and cash equivalents were $159.1 million as of September 30, 2024, down from $185.1 million as of June 30, 2024, providing a cash runway into mid-2027[4] - Cash and cash equivalents increased to $159,095 thousand as of September 30, 2024, up from $28,769 thousand on December 31, 2023[11] - Working capital improved to $145,278 thousand, a significant recovery from a deficit of $(10,004) thousand[11] - Total assets rose to $168,717 thousand, compared to $39,399 thousand at the end of 2023[11] - Total stockholders' equity turned positive at $150,361 thousand, recovering from a deficit of $(84,636) thousand[11] Expenses - Research and development expenses increased to $14.3 million for Q3 2024, compared to $8.1 million for Q3 2023, primarily due to higher external research costs[4] - General and administrative expenses rose to $5.3 million for Q3 2024, up from $2.0 million for Q3 2023, driven by increased personnel-related costs and professional fees[4] Net Loss - The net loss for Q3 2024 was $17.7 million, compared to a net loss of $10.1 million for Q3 2023[4] Clinical Trials - The first subject was dosed with TX000045 in the APEX Phase 2 clinical trial in early October 2024, with topline results expected in 2026[2] - Favorable Phase 1a topline trial results for TX45 were announced in September 2024, showing good tolerability and a favorable pharmacokinetic profile[2] - Development candidate TX2100 was selected for the HHT program, with plans to initiate a Phase 1 clinical trial in Q4 2025 or Q1 2026[2] - Ongoing Phase 1b hemodynamic clinical trial results for TX45 are expected in late Q1 2025 or early Q2 2025[3] - The APEX Phase 2 clinical trial is a 24-week placebo-controlled study evaluating TX45 in subjects with PH-HFpEF[2] Future Outlook - Tectonic anticipates that its current cash position will support key Phase 1b and Phase 2 readouts for TX45 and the progression of the HHT program into clinical development[4]

Clinical Trials - TX45 has advanced into Phase 2 clinical trial for patients with Group 2 PH-HFpEF, with the first site activated and screening open in August 2024[1] - The Phase 1a clinical trial results for TX45 in healthy volunteers are expected to be reported in September 2024[5] - The ongoing Phase 1b clinical trial results for TX45 are expected in mid-2025[11] - The company anticipates topline results from the Phase 2 clinical trial of TX45 in 2026[5] Financial Performance - The company reported a net loss of $12.7 million for Q2 2024, compared to a net loss of $10.5 million for Q2 2023[7] - Net loss for the three months ended June 30, 2024, was $12,671,000, compared to a net loss of $10,455,000 for the same period in 2023, indicating a year-over-year increase of 21.3%[19] - Comprehensive loss for the three months ended June 30, 2024, was $(12,679,000), compared to $(10,455,000) for the same period in 2023, representing an increase of 11.7%[19] Expenses - Research and development expenses for Q2 2024 were $7.1 million, a decrease from $8.8 million in Q2 2023[6] - General and administrative expenses increased to $4.3 million in Q2 2024 from $1.9 million in Q2 2023, primarily due to merger-related activities[7] - Total operating expenses for the three months ended June 30, 2024, were $11,421,000, compared to $10,631,000 for the same period in 2023, representing an increase of 7.4%[19] - Research and development expenses decreased to $7,074,000 for the three months ended June 30, 2024, from $8,766,000 in the same period of 2023, a reduction of 19.3%[19] - Interest expense decreased to $(28,000) for the three months ended June 30, 2024, from $(40,000) in the same period of 2023, a reduction of 30.0%[19] Cash and Assets - As of June 30, 2024, cash and cash equivalents were $185.1 million, expected to provide a cash runway into mid-2027[6] - Total assets as of June 30, 2024, were $19,390,000, compared to $39,399,000 as of December 31, 2023, showing a significant decrease of 50.8%[20] Equity and Shares - Total stockholders' equity (deficit) improved to $(166,367,000) as of June 30, 2024, from $(84,636,000) as of December 31, 2023, indicating a worsening of 96.5%[20] - Weighted-average common shares outstanding increased to 2,919,872 for the three months ended June 30, 2024, from 1,228,778 in the same period of 2023, an increase of 138.8%[19] Mergers and Acquisitions - The company completed a reverse merger with AVROBIO in June 2024, including a concurrent private placement of $130.7 million[3] Future Plans - The company plans to select a development candidate for its second program in Hereditary Hemorrhagic Telangiectasia (HHT) in the second half of 2024[5] Interest Income - Interest income increased to $318,000 for the three months ended June 30, 2024, compared to $224,000 for the same period in 2023, reflecting a growth of 42.0%[19] Liabilities - Change in fair value of SAFE liabilities was $(1,535,000) for the three months ended June 30, 2024, with no comparable figure for the same period in 2023[19]

Financial Performance - The company has incurred net losses of $12.7 million and $10.5 million for the three months ended June 30, 2024 and 2023, respectively, and $27.9 million and $24.9 million for the six months ended June 30, 2024 and 2023, respectively[93]. - The net loss for Q2 2024 was $12.7 million, representing a 21% increase compared to a net loss of $10.5 million in Q2 2023[116]. - The company incurred a net loss of $27.9 million for the six months ended June 30, 2024, compared to a net loss of $24.9 million for the same period in 2023[136]. - The company used $22.7 million and $20.5 million in operations for the six months ended June 30, 2024 and 2023, respectively[146]. Cash and Capital - The company had $185.1 million in cash and cash equivalents as of June 30, 2024, which is expected to fund operations for at least the next twelve months[92]. - The company had $185.1 million in cash and cash equivalents as of June 30, 2024, with an accumulated deficit of $118.5 million[132]. - The company has received $288.6 million in capital contributions since inception, primarily from sales of preferred stock and proceeds from the merger[92]. - Net cash provided by financing activities was $179.1 million for the six months ended June 30, 2024, primarily due to proceeds from the sale of shares and the Merger[139]. Expenses - Research and development expenses include costs related to employee salaries, clinical trials, and compliance with regulatory requirements[105]. - Research and development expenses for Q2 2024 were $7.1 million, a decrease of 19% from $8.8 million in Q2 2023[119]. - Research and development expenses for the six months ended June 30, 2024, totaled $17.9 million, down 18% from $21.8 million in the same period of 2023[125]. - General and administrative expenses increased by 133% to $4.3 million in Q2 2024 from $1.9 million in Q2 2023, primarily due to higher personnel and professional fees[120]. - General and administrative expenses increased to $6.5 million for the six months ended June 30, 2024, compared to $3.4 million in the same period of 2023, marking a 90% increase[129]. - The company anticipates a significant increase in general and administrative expenses in the future due to costs associated with operating as a public company[111]. Research and Development - The company plans to continue the clinical development of its lead product candidate TX45 and expand its clinical product pipeline[93]. - The company is focused on developing biologics to address GPCRs, which represent over 30% of all approved drugs[88]. - The proprietary GEODe™ technology platform aims to overcome challenges in GPCR-targeted drug discovery[89]. - The company expects to incur significant expenses and operating losses as it advances its research programs and product candidates, necessitating additional capital[131]. Merger and Corporate Structure - The merger with AVROBIO was completed on June 20, 2024, resulting in Legacy Tectonic securityholders owning approximately 38.5% of the outstanding shares on a diluted basis[99]. - The increase in professional and consultant fees in Q2 2024 was primarily related to merger-related activities, which rose by 489% to $2.5 million[120]. Liabilities and Obligations - Total contractual obligations and commitments as of June 30, 2024, amount to $3.724 million, including finance leases of $1.243 million and operating leases of $2.481 million[148]. - The company has a one-time license fee of $170,000 under the Harvard License Agreement, with installments due over three years[150]. - The company is obligated to pay up to $8.5 million in milestone payments for products granted FDA marketing authorization under the Harvard License Agreement[152]. - The company has a total of $4.8 million in milestone payments under the Alloy Therapeutics License Agreement for clinical trial advancements[154]. - The SAFE liabilities loss was $3.6 million due to the remeasurement of the SAFE liabilities to fair value during the six months ended June 30, 2024[130]. Interest Income - Interest income increased by 42% to $318,000 in Q2 2024 compared to $224,000 in Q2 2023, driven by higher interest rates[116]. - Interest income increased by $0.2 million for the six months ended June 30, 2024, attributed to rising interest rates[130]. Market Conditions - An immediate 10% change in market interest rates would not have a material effect on the fair market value of the company's investment portfolio[167].

Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tectonic Therapeutic, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code No.) Delaware 2836 81-0710585 (I.R.S. Employer Identification Number) 4 ...

Financial Performance - Net loss for the three months ended March 31, 2024, was $15,221,000, compared to a net loss of $14,445,000 for the same period in 2023, indicating an increase in loss of about 5.4%[6] - The company reported a comprehensive loss of $15,271,000 for the three months ended March 31, 2024, compared to a comprehensive loss of $14,445,000 for the same period in 2023, reflecting an increase of about 5.7%[6] - The total net loss attributable to common stockholders was $15,221,000, compared to a net loss of $14,445,000 for the same period in 2023, representing an increase of approximately 5.4%[81] Assets and Liabilities - Total current assets decreased from $30,884,000 as of December 31, 2023, to $20,558,000 as of March 31, 2024, representing a decline of approximately 33.5%[3] - Total liabilities increased from $43,408,000 as of December 31, 2023, to $50,102,000 as of March 31, 2024, an increase of about 15.3%[3] - Total stockholders' deficit increased from $84,636,000 as of December 31, 2023, to $99,574,000 as of March 31, 2024, an increase of about 17.6%[3] - Cash and cash equivalents decreased from $28,769,000 as of December 31, 2023, to $18,748,000 as of March 31, 2024, a reduction of approximately 34.9%[3] - Cash and cash equivalents decreased to $19.3 million as of March 31, 2024, down from $25.5 million at the end of 2023, representing a decrease of approximately 24%[12] - The aggregate liquidation preference of convertible preferred stock remained at $87,459,000 as of March 31, 2024, consistent with December 31, 2023[3] Research and Development - Research and development expenses for the three months ended March 31, 2024, were $10,818,000, down from $12,985,000 for the same period in 2023, a decrease of approximately 16.8%[6] - The company expects to continue incurring operating losses and negative cash flows as it develops its product candidates[16] - The company’s proprietary GEODe™ platform is currently in development, focusing on therapeutic proteins and antibodies targeting GPCRs[14] - The company anticipates needing to raise additional capital to fund its operations as it continues its research and development efforts[16] Cash Flow and Operating Activities - The company utilized $9.3 million in cash from operating activities during the first quarter of 2024, an improvement from $10.8 million used in the same period of 2023[12] - The Company paid $381,000 in operating cash flows for operating leases during the three months ended March 31, 2024, compared to $370,000 in the same period of 2023[53] Equity and Stock - The weighted-average common shares outstanding increased from 2,222,800 for the three months ended March 31, 2023, to 2,608,740 for the same period in 2024, an increase of approximately 17.3%[6] - The Company has issued a total of 6,825,483 shares of Preferred Stock with a carrying value of $80,627,000 as of March 31, 2024[57] - The Company has authorized the issuance of up to 11,947,558 shares of common stock, with 2,637,120 shares issued and outstanding as of March 31, 2024[67] - The 2019 Equity Incentive Plan allows for the issuance of up to 1,991,264 shares of common stock, with stock options being the only equity awards issued to date[68] - The total stock-based compensation expense for the three months ended March 31, 2024, was $321,000, up from $275,000 in 2023, indicating a year-over-year increase of approximately 16.7%[77] Mergers and Acquisitions - The company completed a merger with AVROBIO, Inc. on June 20, 2024, receiving $77.3 million in cash and completing the sale of $96.6 million in common stock[16] - The company entered into a merger agreement with AVROBIO on January 30, 2024, with the merger closing on June 20, 2024, treating AVROBIO as the acquired company for financial reporting purposes[91] - Concurrently with the merger, certain investors purchased 7,790,889 shares of the company's common stock for an aggregate purchase price of approximately $96.6 million[92] Fair Value and Liabilities - The company incurred a change in the fair value of SAFE liabilities amounting to a loss of $2,075,000 for the three months ended March 31, 2024[6] - As of March 31, 2024, the SAFE liabilities were valued at $32.59 million, up from $30.52 million as of December 31, 2023, reflecting a fair value adjustment of $2.08 million[31] - The fair value of the SAFEs issued in October 2023 was recognized at $10.4 million, with subsequent measurement resulting in total SAFE liabilities fair value of $32.6 million recorded in the statement of operations[87] Commitments and Expenses - The Company has commitments for annual maintenance fees and royalty payments under its agreements with Harvard and Alloy Therapeutics, which may total in the low seven digits annually[42][46] - The Company has a remaining installment of $56,668 due to Harvard in July 2024 as part of a license agreement[42] - Total lease costs for the three months ended March 31, 2024, amounted to $921,000, an increase of 4.3% compared to $883,000 for the same period in 2023[52] Depreciation and Fair Value Adjustments - Depreciation expense for the three months ended March 31, 2024, was $0.3 million, compared to $0.2 million for the same period in 2023[36] - The company recorded a change in the fair value of SAFE liabilities amounting to $2.1 million for the first quarter of 2024[12] Tax Assets - The company has maintained a full valuation allowance against its net deferred tax assets as of March 31, 2024, due to cumulative net losses and the likelihood of not realizing the benefits of these assets[79]

Group 1 - Avrobio is preparing for a merger with Tectonic Therapeutic, which is set to take place today after investor approval [1] - A one-for-12 reverse stock split will occur after market close today, with shares trading on a split-adjusted basis starting tomorrow [2] - The stock ticker will change from AVRO to TECX following the merger, with Tectonic Therapeutic becoming a wholly-owned subsidiary of Avrobio [2] Group 2 - AVRO stock experienced slight increases in the morning, but there were reports of a significant drop in pre-market trading, possibly due to merger and reverse stock split plans [2]

Financial Performance - The company has incurred a net loss of $6.8 million for the three months ended March 31, 2024, compared to a net loss of $25.0 million for the same period in 2023, resulting in an accumulated deficit of $484.1 million as of March 31, 2024[112]. - Net loss for the three months ended March 31, 2024, was $6.8 million, compared to a net loss of $25.0 million for the same period in 2023, an improvement of $18.2 million[129]. - Interest income increased to $1.1 million for the three months ended March 31, 2024, from $0.3 million for the same period in 2023, an increase of $0.8 million[132]. - Cash and cash equivalents as of March 31, 2024, were $90.5 million[140]. - Net cash used in operating activities was $7.6 million for the three months ended March 31, 2024, compared to $20.3 million for the same period in 2023[143]. Research and Development - Research and development expenses totaled $683,000 for the three months ended March 31, 2024, significantly down from $17.3 million for the same period in 2023[120]. - Research and development expenses decreased by approximately $16.7 million to $0.7 million for the three months ended March 31, 2024, from $17.3 million for the same period in 2023[130]. - The company has terminated all treatment-related and long-term follow-up clinical studies for its Gaucher disease and Fabry disease programs, and discontinued its Hunter syndrome gene therapy program[107]. - The company expects substantial increases in expenses if product development resumes, particularly for preclinical activities and clinical trials[146]. - The establishment of a sales, marketing, and distribution infrastructure is necessary for the commercialization of product candidates[147]. Strategic Plans and Mergers - The company plans to halt development of its gene therapy programs and explore strategic alternatives, including potential mergers or acquisitions[106]. - A merger agreement has been entered into with Tectonic, with certain investors agreeing to purchase shares at a price of $12.39908 per share, totaling approximately $130.7 million in private financings[108]. - The merger is subject to approval by stockholders and is conditioned upon receiving cash proceeds of not less than $114.5 million[109]. - Future operations are highly dependent on the success of the merger, with no assurances that it will be consummated[110]. Funding and Expenses - The company has received gross cash proceeds of $428.1 million from sales of common stock through its IPO and follow-on offerings, and $87.5 million from the sale of its cystinosis gene therapy program[111]. - The company has not generated any product revenue since its inception in 2015 and relies on external funding to support operations[111]. - The company anticipates an increase in general and administrative expenses as it resumes development of product candidates and increases headcount[125]. - General and administrative expenses were $7.3 million for the three months ended March 31, 2024, compared to $7.9 million for the same period in 2023, a decrease of $0.6 million[131]. - Total operating expenses decreased by $17.3 million to $7.9 million for the three months ended March 31, 2024, from $25.2 million for the same period in 2023[129]. Currency and Financial Risk - The company recognized foreign currency transaction losses of $13, and $28 for the three months ended March 31, 2024, and 2023, respectively[154]. - A 10% change in the exchange rate between the U.S. dollar and other currencies is not expected to materially impact the financial position or results of operations[154]. - The company may finance cash needs through equity offerings, debt financings, and collaboration agreements, which could involve relinquishing valuable rights[148]. - The company has not entered into any foreign currency hedging contracts to mitigate exposure to foreign currency exchange risk[155]. Operational Considerations - Additional personnel will need to be hired and retained to support clinical, medical, and commercial operations[147]. - The company may need to delay or limit product development if additional funds are not raised when needed[148]. - There were no material changes to the company's critical accounting policies during the three months ended March 31, 2024[150].

Merger and Ownership Structure - AVROBIO securityholders are expected to own approximately 22.3% of the combined company, while former Tectonic securityholders are expected to own approximately 39.8%[61]. - The merger agreement includes an exchange ratio based on AVROBIO's net cash at closing, anticipated to be between $65.0 million and $75.0 million[61]. - If AVROBIO's net cash is below $65.0 million, the exchange ratio will be adjusted, resulting in a smaller ownership percentage for AVROBIO stockholders[61]. - The merger cannot be consummated without the approval of certain proposals by AVROBIO stockholders[63]. - Following the merger, AVROBIO stockholders are expected to own approximately 22.3% of the combined company, while former Tectonic stockholders are expected to own approximately 39.8%[67]. - AVROBIO anticipates its net cash at closing will be between $65.0 million and $75.0 million, with ownership percentages based on an assumption of $65.0 million[67]. - If the merger is not completed, AVROBIO may be required to pay Tectonic a termination fee of $2,712,500, or Tectonic may owe AVROBIO $4,900,000[67]. - The completion of the merger is subject to various conditions, including approval from both AVROBIO and Tectonic stockholders[75]. Financial Performance and Capital Requirements - AVROBIO incurred a net loss of $105.9 million for the year ended December 31, 2022, and a net income (loss) of $12.2 million for the year ended December 31, 2023[78]. - AVROBIO has received a cash payment of $87.5 million from Novartis for the sale of its cystinosis gene therapy program, which has allowed the company to pay off all outstanding amounts under its Term Loan Agreement[78]. - The combined company may need to raise additional capital, potentially causing significant dilution to existing shareholders[64]. - AVROBIO's future capital requirements will depend on various factors, including the costs associated with drug discovery, clinical trials, and potential regulatory reviews[82]. - The company may need additional funding to resume development of its product candidates, which may not be available on acceptable terms[82]. - AVROBIO's exploration of strategic alternatives may involve entering into acquisitions or mergers, which could result in dilution for existing stockholders[83]. Strategic Alternatives and Operational Focus - In July 2023, AVROBIO announced a comprehensive exploration of strategic alternatives to maximize stockholder value, including a proposed merger with Tectonic announced in January 2024[79]. - AVROBIO's management and employees are currently focused on the merger, which may divert attention from day-to-day operations[74]. - The company has halted further development of its programs and conducted reductions in force while evaluating strategic alternatives[82]. - AVROBIO's cash conservation activities may lead to unintended consequences, including employee attrition and reduced morale[78]. - The company has implemented workforce reductions to conserve capital expenditures, but may not realize the anticipated savings or operational efficiencies from these restructuring efforts[87]. Clinical Development and Regulatory Challenges - AVROBIO's clinical development has been halted, and the commercially-scalable plato platform has been used in only two clinical trials[96]. - The company has limited experience in preparing and submitting regulatory filings, having never completed a pivotal or registrational clinical trial[92]. - The regulatory approval process for AVROBIO's novel product candidates may be more expensive and time-consuming compared to other therapies, with limited prior approvals in the HSC gene therapy space[90]. - AVROBIO's ability to conduct clinical trials may be impacted by changes in hospital policies, government regulations, and disruptions in third-party services[89]. - The company may face significant delays in resuming clinical trials due to challenges in patient enrollment, particularly for rare diseases[94]. Intellectual Property and Competitive Landscape - AVROBIO's ability to compete effectively depends on maintaining proprietary technology and manufacturing processes[129]. - The company may face substantial litigation expenses and resource diversion if claims of patent infringement arise[128]. - AVROBIO's reliance on trade secrets and confidentiality agreements poses risks, as these can be difficult to enforce[129]. - Changes in U.S. patent law, particularly the Leahy-Smith America Invents Act, could increase uncertainties and costs related to patent applications and enforcement, potentially adversely affecting AVROBIO's business[130]. - AVROBIO's ability to protect its intellectual property may be compromised if it cannot secure patent term extensions or data exclusivity for its product candidates, which could lead to reduced revenue[132]. Market and Economic Conditions - The market price of AVROBIO common stock is subject to significant fluctuations, particularly in the context of the merger's completion[66]. - AVROBIO's stock price may decline if the market assumes the merger will not be completed[73]. - The company is subject to provisions in its charter and bylaws that could delay or prevent a change in control, including the authorization of "blank check" preferred stock and a classified board of directors[138]. - AVROBIO's financial condition could be adversely affected by unfavorable global economic conditions, including the impacts of the COVID-19 pandemic and geopolitical events[141]. - The company has faced cybersecurity threats in the past, including a cyberattack in 2017 that led to the theft of funds, which could disrupt operations if similar incidents occur in the future[141]. Compliance and Regulatory Risks - AVROBIO is subject to various U.S. and foreign healthcare laws, and non-compliance could result in substantial penalties and reputational harm[120]. - Compliance with data protection laws, including GDPR, is critical, as violations could result in fines up to 4% of global revenues or €20 million[122]. - The company may need to enhance its business processes and systems to support future growth and ensure compliance with regulatory requirements[120]. - AVROBIO's suppliers have not undergone FDA approval processes, which poses risks for the company's ability to meet regulatory requirements[109]. Employee and Management Issues - AVROBIO has implemented workforce reductions, including a 50% reduction in July 2023 and further cuts in October, November, and December 2023, impacting employee morale and retention[118]. - The company is currently led by an interim CEO following the resignation of the former President and CEO on May 1, 2023, with no timeline for hiring a permanent replacement[118]. - AVROBIO's ability to retain key personnel is critical for its future success, with a competitive landscape for skilled employees in the biotechnology sector[118].

Merger Details - AVROBIO and Tectonic Therapeutic have entered into a definitive merger agreement in an all-stock transaction, with AVROBIO acquiring 100% of Tectonic's equity [1] - The combined company will operate under the name Tectonic Therapeutic, Inc and trade on Nasdaq under the ticker symbol "TECX" [1] - Tectonic has raised $130.7 million in a private placement, with the combined company expected to have approximately $165 million in cash and cash equivalents at closing [1] Strategic Rationale - The merger enhances Tectonic's ability to advance its clinical-stage Fc-relaxin fusion protein, TX45, and other pipeline assets [2] - Tectonic's GEODeTM platform enables the discovery of biologics targeting challenging GPCRs, which are central to human biology and the target of over 30% of approved drugs [2][3] - The combined company is expected to have sufficient cash to fund operations into mid-2027 [1] Tectonic's Pipeline - TX45, a potential best-in-class Fc-relaxin fusion protein, is being developed for Group 2 Pulmonary Hypertension in HFpEF patients, affecting over 600,000 people in the US [4] - Phase 1a data for TX45 has shown promising PK/PD effects, with Phase 1b and Phase 2 data expected in 2025 and 2026, respectively [5] - Tectonic's second program targets Hereditary Hemorrhagic Telangiectasia (HHT), affecting approximately 75,000 patients in the US, with human studies planned for late 2025 to early 2026 [5] - A third program focuses on fibrosis using a bispecific approach to inhibit two different receptors [5] Financial and Organizational Structure - Post-merger, AVROBIO shareholders will own approximately 22.3% of the combined company, while Tectonic shareholders will own approximately 40.2% [6] - The combined company will be led by Tectonic's management team, with one AVROBIO board member joining the new board [7] - The merger is expected to close in Q2 2024, subject to shareholder approvals and other customary closing conditions [7] Advisors - Leerink Partners is serving as exclusive financial advisor to Tectonic, with Cooley LLP as legal counsel [8] - Piper Sandler is acting as capital markets advisor to Tectonic, while TD Cowen and Houlihan Lokey are serving as financial advisors to AVROBIO [8]